AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14253279
Drug: Hydroxyurea administered
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea administered parenterally
Trial: 14253279
Drug: Hydroxyurea at
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea at 25.0, 37.5, and 50.0 mg/kg
Trial: 14253279
Drug: Hydroxyurea at
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea at 12.5 mg/kg (low dose)
Trial: 344159
Drug: Glucagon (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (2 X 5 mg protamine-zinc glucagon intramuscularly per day)
Trial: 29949284
Drug: Pertubation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertubation treatment
Trial: 19967596
Drug: 6.4% carbohydrate‐electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.4% carbohydrate‐electrolyte solution
Trial: 15126989
Drug: High-dose rhASB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rhASB (1.0 mg/kg)
Trial: 15126989
Drug: Low-dose rhASB
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rhASB (0.2 mg/kg)
Trial: 12641012
Drug: Dose around
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose around 20 Gy of brachytherapy
Trial: 12641012
Drug: Controlled dose
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled dose escalation of brachytherapy
Trial: 9817690
Drug: Methylprednisolone treatment
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone treatment (n = 11)
Trial: 2570971
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol patches (2 x 100 micrograms) with norethisterone 5 mg from day 19-26 of the cycle
Trial: 2570971
Drug: Placebo patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches with norethisterone 5 mg from day 19-26 of the cycle
Trial: 1233519
Drug: Oral diazepam,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam, 30 mgs. daily
Trial: 30157115
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral iron supplementation (Control)
Trial: 30157115
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplementation in hypertensive participants
Trial: 30157115
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplementation in hypertensive participants without anemia
Trial: 28501522
Drug: Flosequinan (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flosequinan (75 or 100 mg/day)
Trial: 9872520
Drug: OAC (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC (500 mg t.i.d. amoxicillin, 200 mg t.i.d. clarithromycin, 20 mg q.d. omeprazole)
Trial: 9872520
Drug: Ox2AC (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ox2AC (500 mg t.i.d. amoxicillin, 200 mg t.i.d. clarithromycin, 20 mg b.i.d. omeprazole)
Trial: 9872520
Drug: OACS (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OACS (500 mg t.i.d. amoxicillin, 200 mg t.i.d. clarithromycin, 20 mg q.d. omeprazole, 100 mg t.i.d. sofalcone)
Trial: 7913155
Drug: Salmeterol xinafoate
RxNorm normalized name: Salmeterol Xinafoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol xinafoate (50 micrograms twice daily) plus BDP
Trial: 7913155
Drug: Higher-dose BDP
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose BDP (500 micrograms twice daily)
Trial: 2915235
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (repetitive pulse vincristine, dactinomycin, and cyclophosphamide (VAC) for 2 years)
Trial: 2915235
Drug: Standard VAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard VAC therapy for 2 years or VA for 1 year (Control)
Trial: 1104047
Drug: Atenolol 200
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 200 mg/day
Trial: 1104047
Drug: Atenolol 400
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 400 mg/day
Trial: 1104047
Drug: Atenolol 200
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 200 mg/day with bendrofluazide 5 mg/day
Trial: 1104047
Drug: Bendrofluazide 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide 5 mg/day
Trial: 21987394
Drug: Gantenerumab 60
RxNorm normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gantenerumab 60 mg
Trial: 21987394
Drug: Gantenerumab 200
RxNorm normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gantenerumab 200 mg
Trial: 20367671
Drug: Hydroglycolic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroglycolic extract of Piptadenia colubrina (HEPC) in a gel-cream formulation
Trial: 15909264
Drug: Antifungal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal therapy (mold-active antifungal drugs)
Trial: 108715
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg haloperidol intravenous (IV)
Trial: 108715
Drug: 0.50 mg
RxNorm normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 mg haloperidol intravenous (IV)
Trial: 108715
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg haloperidol intramuscular (IM)
Trial: 108715
Drug: 0.50 mg
RxNorm normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 mg haloperidol intramuscular (IM)
Trial: 30745518
Drug: Fosravuconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosravuconazole (100 mg orally once a day for 12 weeks)
Trial: 28599665
Drug: Omega-3 PUFAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFAs capsules (1.8g EPA and 1.2g DHA)
Trial: 25796419
Drug: Silver sucrose
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Silver sucrose octasulfate nasal gel (Silsos gel®)
Trial: 25022114
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (acupuncture and auricle cutting)
Trial: 18322606
Drug: Routine medications
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medications
Trial: 6544198
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg sulindac twice daily
Trial: 22101443
Drug: Ward care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ward care (for patients with anaerobic threshold >= 11 ml oxygen per kg per min)
Trial: 20696797
Drug: Quality Initiative
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Quality Initiative in Rectal Cancer strategy
Trial: 14555886
Drug: Beta-blocker bisoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker bisoprolol (5 mg/day)
Trial: 9307933
Drug: 3.8 g
RxNorm normalized name: dextrin 3 gram/3.8 gram ORAL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.8 g highly purified EPA
Trial: 9307933
Drug: 3.6 g
RxNorm normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 g DHA
Trial: 8165609
Drug: Bay u3405
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bay u3405 (thromboxane A2 receptor antagonist)
Trial: 3532011
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 micrograms twice daily via pear spacer (PS)
Trial: 3532011
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 micrograms twice daily directly from metered dose inhaler
Trial: 27654255
Drug: Vintafolide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vintafolide (2.5 mg intravenously, 3 times per week, weeks 1 and 3, every 28 days) + Pegylated Liposomal Doxorubicin (50 mg/m intravenously, day 1, every 28 days)
Trial: 27654255
Drug: Pegylated Liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated Liposomal Doxorubicin alone (50 mg/m intravenously, day 1, every 28 days)
Trial: 27654255
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Vintafolide + PLD)
Trial: 19935406
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid at doses of 15, 30, and 50 mg/kg per day
Trial: 17931082
Drug: Alikal Dolor
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alikal Dolor (effervescent powder containing paracetamol 500 mg/sodium bicarbonate 2318 mg)
Trial: 17931082
Drug: Parageniol (paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parageniol (paracetamol 500 mg coated tablets)
Trial: 15848672
Drug: Prograf twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prograf twice a day (days 14 and 42)
Trial: 15848672
Drug: MR tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MR tacrolimus once daily (days 28 and 56)
Trial: 15848672
Drug: Prograf twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prograf twice a day (day 14)
Trial: 15848672
Drug: MR tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MR tacrolimus once daily (day 28)
Trial: 15848672
Drug: Prograf twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prograf twice a day (day 42)
Trial: 15848672
Drug: MR tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MR tacrolimus once daily (day 56)
Trial: 11973248
Drug: Corticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment for up to 6 weeks
Trial: 11973248
Drug: Corticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment for 4 or more weeks
Trial: 30717690
Drug: Intravenous Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Iron sucrose complex (ISC)
Trial: 28527704
Drug: PF-00547659 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00547659 7.5 mg
Trial: 28982740
Drug: PF-00547659 22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00547659 22.5 mg
Trial: 28982740
Drug: PF-00547659 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00547659 75 mg
Trial: 28982740
Drug: PF-00547659 225
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00547659 225 mg
Trial: 25746580
Drug: α‐adrenergic agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α‐adrenergic agonist (midodrine) plus an anticholinergic (solifenacin)
Trial: 25746580
Drug: α‐adrenergic agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α‐adrenergic agonist only
Trial: 16974184
Drug: Olanzapine (OLZ)
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine (OLZ) 10-20 mg/d
Trial: 16974184
Drug: Quetiapine (QUE)
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine (QUE) 300-700 mg/d
Trial: 11279409
Drug: Off-pump treatment
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Off-pump treatment on the beating heart
Trial: 11279409
Drug: On-pump treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-pump treatment with conventional cardiopulmonary bypass
Trial: 9253309
Drug: Carbimazole by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbimazole by a titration regimen (Group A, n = 30)
Trial: 9253309
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of carbimazole plus T4 (Group B, n = 30)
Trial: 8463869
Drug: Polysaccharide-free diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysaccharide-free diet with 20 g of unabsorbed sugar lactulose
Trial: 8463869
Drug: Polysaccharide-free diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysaccharide-free diet with 20 g of fermentable fiber, guar
Trial: 2834257
Drug: Morphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.1 mg/kg every 6 h s.c.)
Trial: 2834257
Drug: Naloxone (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.8 mg every 6 h s.c.)
Trial: 2834257
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline 1 ml every 6 h s.c.)
Trial: 28158200
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control tool (CC)
Trial: 25171663
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose triamcinolone hexacetonide (20 mg)
Trial: 25171663
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose triamcinolone hexacetonide (40 mg)
Trial: 9035015
Drug: Etodolac 200
RxNorm normalized name: etodolac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 200 mg bid (E200)
Trial: 9035015
Drug: Etodolac 300
RxNorm normalized name: etodolac 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 300 mg bid (E300)
Trial: 9035015
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg qd (P20)
Trial: 27402235
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose edoxaban
Trial: 27402235
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose edoxaban
Trial: 26386790
Drug: NOACs (meta-analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOACs (meta-analysis of 4 warfarin-controlled phase 3 AF trials)
Trial: 21534652
Drug: Internet-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based therapy (TAO)
Trial: 2865187
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral contraceptive
Trial: 14564679
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg/d for 12 weeks
Trial: 10964188
Drug: Complementary therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary therapies (specific therapies not detailed)
Trial: 10964188
Drug: Complementary therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary therapy research methods
Trial: 1620831
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 160‐mL dose of Optiray 320 (ioversol) at 3.0 mL/sec (group 1)
Trial: 1620831
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 160‐mL dose of Optiray 320 (ioversol) at 4.5 mL/sec (group 2)
Trial: 6736339
Drug: Oral 8‐methoxypsoralen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 8‐methoxypsoralen photochemotherapy (PUVA)
Trial: 31237065
Drug: Ultramicronized palmitoylethanolamide
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultramicronized palmitoylethanolamide (PEA-um) 15 mg/kg per os, once daily; n=29
Trial: 26718899
Drug: VAC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC therapy in venous ulcers
Trial: 25163699
Drug: 1.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg/kg lexaptepid
Trial: 22161738
Drug: Iloperidone 10-16
RxNorm normalized name: iloperidone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloperidone 10-16 mg/day
Trial: 22161738
Drug: Iloperidone 20-24
RxNorm normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloperidone 20-24 mg/day
Trial: 22161738
Drug: Iloperidone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloperidone (all doses)
Trial: 22161738
Drug: Iloperidone (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloperidone (higher doses)
Trial: 17095745
Drug: Acetazolamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (250 mg every 8 h for 3 days)
Trial: 17598699
Drug: Test FDC
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test FDC (Esomeprazole 40 mg and Domperidone 30 mg)
Trial: 17598699
Drug: Reference FDC
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference FDC (Esomeprazole 40 mg and Domperidone 30 mg)
Trial: 9728854
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of clonidine (4 microg/kg in 20 min followed by 2 microg x kg(‐1) x h(‐1))
Trial: 9728854
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of sufentanil (0.2 microg x kg(‐1) x h(‐1))
Trial: 9728854
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of ketamine (0.5 mg/kg followed by 0.25 mg x kg(‐1) x h(‐1))
Trial: 9728854
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of bupivacaine (7 mL of 0.5% followed by 5 mL/h of 0.25%)
Trial: 2658536
Drug: Xylitol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol (30 g in 200 mL water)
Trial: 2658536
Drug: Glucose (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (30 g in 200 mL water)
Trial: 2658536
Drug: Xylitol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol (30 g)
Trial: 10944
Drug: Hydrochloride preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochloride preparation of oxytetracycline
Trial: 10944
Drug: Film-coated tablets
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film-coated tablets of oxytetracycline dihydrate
Trial: 10944
Drug: Sugar-coated tablets
RxNorm normalized name: tiopronin
DrugBank: Tiopronin (DB06823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sugar-coated tablets of oxytetracycline dihydrate
Trial: 30329224
Drug: CKD-395 0.5/1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-395 0.5/1000 mg
Trial: 30329224
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of lobeglitazone sulfate 0.5 mg and metformin HCl XR 1000 mg
Trial: 26011583
Drug: High-frequency EMA
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency EMA (six times daily)
Trial: 26011583
Drug: Low-frequency EMA
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency EMA (once daily)
Trial: 21959871
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus chemotherapy for all HER2-positive populations
Trial: 21959871
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus chemotherapy for IHC 2+/FISH+ or IHC 3+ population
Trial: 21959871
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus chemotherapy for IHC 3+ population
Trial: 19843557
Drug: ALVAC-HIV (vCP1521)
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALVAC-HIV (vCP1521) plus AIDSVAX B/E vaccine regimen
Trial: 12142757
Drug: Intraoperative retrobulbar
RxNorm normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative retrobulbar 95% ethanol injections
Trial: 9990383
Drug: Topical betamethasone‐17‐valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betamethasone‐17‐valerate
Trial: 9626025
Drug: Formoterol 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 24 micrograms twice daily